Abstract：Objective To study the clinical value of Erlotinib first-line treatment for elderly patients with non-small cell lung cancer with chronic obstructive pulmonary disease （COPD）.Methods 80 cases of elderly patients with nonsmall cell lung cancer patientswith COPD from January 2012 to March 2013 were selected and randomly divided into Erlotinib group and chemotherapy group，patients were treated by Erlotinib first-line treatment and chemotherapy respectively.The efficacy and toxic and side effect of treatment between two groupswere compared，and patientswere followed up，the lifetime of patients between two groups were searched.Results The effective rate of the Erlotinib group was significantly higher than that of the chemotherapy group（χ2=4.2667，P=0.0389），the control rate was also significantly higher than that of the chemotherapy group （χ2=4.7127，P=0.0299）.The incidence ofmyelosuppression and gastrointestinal reaction in the Erlotinib group were significantly lower than those in the chemotherapy group （χ12=20.3135，P= 0.0000；χ22=4.0525，P=0.0441）；the incidence of rash between two groups was significant difference （χ2=13.0909，P= 0.0003）.Progression-free survival（PFS）and overall survival（OS）in the Erlotinib group were significantly longer than those in the chemotherapy group，the difference was statistically significant（t1=3.2579，P=0.0017；t2=6.3139，P=0.0000）. Conclusion Erlotinib first-line treatment for elderly patientswith non-small cell lung cancer with COPD has good effect，whih can significantly improve the treatmentefficiency，reduce the incidence of toxic and side effect，prolong lifetime of patients.
曾昭墩. 厄洛替尼一线治疗老年非小细胞肺癌合并慢性阻塞性肺疾病临床价值探讨[J]. 中国当代医药, 2016, 23(26): 46-48.
ZENG Zhao-dun. The clinical value of Erlotinib first-line treatment for elderly patients with non-small cell lung cancer with chronic obstructive pulmonary disease. 中国当代医药, 2016, 23(26): 46-48.
=20.3135，P=0.0000；
京公网安备 11010502046607号